NeRRe Therapeutics
PrivateLast Round
Series B
Extension
Jul 7, 2021
Total Funding Raised
$74.73M
Company Overview
NeRRe Therapeutics operates in Healthcare & Life Sciences and is based in Stevenage. Its latest recorded funding round was a Series B Extension round in July 2021.
NeRRe Therapeutics is a clinical-stage biotechnology company that develops a portfolio of neurokinin receptor antagonists to treat debilitating conditions caused by neuronal hypersensitivity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeRRe Therapeutics Comparables
Compare NeRRe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axalbion | 85% | |
| Nocion Therapeutics | 81% | |
| Melius Pharma | 79% |
For institutional investors. Book with your work email.
NeRRe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jul 7, 2021 | ||||
| Series B | Jan 5, 2017 | ||||
| Series A | Dec 19, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeRRe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B Extension, Series B |
| Forbion | Series B Extension, Series B |
| Future Fund | Series B Extension |
| Advent Life Sciences | Series B Extension, Series B |
| Fountain Healthcare Partners | Series B Extension, Series B |
| OrbiMed | Series B Extension, Series B |
| Advent Venture Partners | Series A |
For institutional investors. Book with your work email.
NeRRe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeRRe Therapeutics's valuation, stock price, and market status.
Is NeRRe Therapeutics a public or private company?
NeRRe Therapeutics is a private company.
What is the current stock price of NeRRe Therapeutics?
NeRRe Therapeutics is a private company, so its shares have no public market price. Caplight tracks NeRRe Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeRRe Therapeutics worth (valuation)?
Valuation information for NeRRe Therapeutics is not publicly available.
Can I buy NeRRe Therapeutics stock?
NeRRe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeRRe Therapeutics's last funding round?
NeRRe Therapeutics's most recent funding round was Series B Extension on July 7, 2021.
Who are the main investors in NeRRe Therapeutics?
Key investors in NeRRe Therapeutics include Columbus Venture Partners.
Will NeRRe Therapeutics IPO soon?
No public IPO plans have been announced for NeRRe Therapeutics.
How can I track NeRRe Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NeRRe Therapeutics's shares on secondary markets.